Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000031.xml
Download PDF
Klin Monbl Augenheilkd 2025; 242(11): 1059-1060
DOI: 10.1055/a-2697-7878
DOI: 10.1055/a-2697-7878
Statement
Photobiomodulation bei AMD
Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbandes der Augenärzte Deutschlands. Stand 04.07.2025Photobiomodulation for AMDStatement of the German Society of Ophthalmology, the German Retina Society and the German Professional Association of Ophthalmologists. Status 4 July 2025Authors
Die sog. Photobiomodulation (PBM) basiert auf der Interaktion von Licht unterschiedlicher Wellenlänge mit zellulären Strukturen und molekularen Bestandteilen. Der Begriff Photobiomodulation ist nur vage definiert, als Synonym wird auch die Low-Level-Lasertherapie verwendet. Die PBM ist Gegenstand vieler Untersuchungen in der Medizin, um degenerative Prozesse zu verlangsamen oder aufzuhalten.
Publication History
Article published online:
07 November 2025
© 2025. Thieme. All rights reserved.
Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
-
Literatur
- 1 Henein C, Steel DH. Photobiomodulation for non-exudative age-related macular degeneration. Cochrane Database Syst Rev 2021; (05) CD13029
- 2 Chen KY, Lee HK, Chan HC. et al. Is Multiwavelength Photobiomodulation Effective and Safe for Age-Related Macular Degeneration? A Systematic Review and Meta-Analysis. Ophthalmol Ther 2025; 14: 969-987
- 3 Fuma S, Murase H, Kuse Y. et al. Photobiomodulation with 670 nm light increased phagocytosis in human retinal pigment epithelial cells. Mol Vis 2015; 21: 883-892
- 4 Mansouri V, Razzaghi M, Rostami-Nejad M. et al. Neuroprotective Properties of Photobiomodulation in Retinal Regeneration in Rats: Perspectives From Interaction Levels. J Lasers Med Sci 2020; 11: 280-286
- 5 Grisanti S, Bartz-Schmidt KU, Heimann H. et al. Letter to the Editor Regarding „LIGHTSITE II Randomized Multicenter Trial: Evaluation of Multiwavelength Photobiomodulation in Non-exudative Age-Related Macular Degeneration“. Ophthalmol Ther 2024; 13: 1051-1053
- 6 Feltgen N, Ach T, Bartz-Schmidt U. et al. Letter to the Editor: LIGHTSITE III: 13-Month Efficacy and Safety Evaluation of Multiwavelength Photobiomodulation in Nonexudative (Dry) Age-Related Macular Degeneration Using the LumiThera™ Valeda Light Delivery System. Retina Phila Pa 2024;
- 7 Sadda SR. Photobiomodulation for Age-Related Macular Degeneration. JAMA Ophthalmol 2025; 143: 195-196
- 8 Rassi TNO, Barbosa LM, Pereira S. et al. Photobiomodulation efficacy in age-related macular degeneration: a systematic review and meta-analysis of randomized clinical trials. Int J Retina Vitreous 2024; 10: 54
- 9 Boyer D, Hu A, Warrow D. et al. LIGHTSITE III: 13-Month Efficacy and Safety Evaluation of Multiwavelength Photobiomodulation in Nonexudative (Dry) Age-Related Macular Degeneration Using the Lumithera Valeda Light Delivery System. Retina Phila Pa 2024; 44: 487-497
- 10 Rodriguez DA, Song A, Bhatnagar A. et al. Photobiomodulation Therapy for Non-exudative Age-related Macular Degeneration. Int Ophthalmol Clin 2025; 65: 47-52
- 11 U.S. Food and Drug Administration. In: DEN230083, Valeda Light Delivery System. 2024. LumiThera, Inc.